Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CASP1 | P29466 | 8/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155003 | 0.99 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL14433707 | 0.99 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL4430771 | 0.99 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL10868042 | 0.93 | CAPN1 (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL614741 | 0.92 | CASP3 (0.62) | MMEECE1CTSKCASP1CASP3 | |
| SCHEMBL3140616 | 0.92 | CASP3 (0.62) | MMEECE1CTSKCASP1CASP3 | |
| SCHEMBL24992811 | 0.90 | MME (0.59) | MMEECE1CTSKCAPN1PSMB8 | |
| SCHEMBL20263591 | 0.90 | MME (0.59) | MMEECE1CTSKCAPN1PSMB8 | |
| SCHEMBL20677213 | 0.90 | MME (0.59) | MMEECE1CTSKCAPN1PSMB8 | |
| SCHEMBL14371944 | 0.90 | MME (0.59) | MMEECE1CTSKCAPN1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802850-B1 | DEVICES AND SYSTEMS FOR GASTROINTESTINAL MICROBIOME DETECTION AND MANIPULATION | BT BIDCO INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250082265-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | BT BIDCO, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| US-12150775-B2 | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | BIORA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118873822-A | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240335644-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE | GLAS USA LLC | 2024-10-10 | — | — | US | disclosed |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | BIORA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4410832-A2 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | Biora Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-110430801-B | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-112400024-B | Device and system for gastrointestinal microbiome detection and processing | 比奥拉治疗股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | GLAS USA LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230019619-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TLR MODULATOR | GLAS USA LLC | 2023-01-19 | — | — | US | disclosed |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4108183-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE | Biora Therapeutics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11523772-B2 | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | BIORA THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11426566-B2 | Treatment of a disease of the gastrointestinal tract with a TLR modulator | BIORA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | GLAS USA LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BT BIDCO LLC | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019619-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TLR MODULATOR | TLR6, TLR5, TLR9 | MME 2495/4885ECE1 4291/4885CTSK 1461/4885 |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | FABP2, SI, MLNR | MME 611/4885ECE1 1479/4885CTSK 355/4885 |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | FABP2, IL2, TSLP | MME 1110/4885ECE1 4102/4885CTSK 778/4885 |
| US-11426566-B2 | Treatment of a disease of the gastrointestinal tract with a TLR modulator | TLR6, TLR5, TLR9 | MME 2495/4885ECE1 4291/4885CTSK 1461/4885 |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | SI, VIP, MLN | MME 1565/4885ECE1 1998/4885CTSK 205/4885 |
| US-20250082265-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | MME 1459/4885ECE1 3732/4885CTSK 960/4885 |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | ACKR3, CXCR2, CXCR3 | MME 681/4885ECE1 1416/4885CTSK 689/4885 |
| US-20240335644-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE | CD40LG, CD40, ICOS | MME 1105/4885ECE1 1408/4885CTSK 413/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | MME 1686/4885ECE1 1255/4885CTSK 888/4885 |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | FABP2, SI, MLNR | MME 611/4885ECE1 1479/4885CTSK 355/4885 |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | MME 1459/4885ECE1 3732/4885CTSK 960/4885 |
| US-11523772-B2 | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | TPMT, FABP2, SLC10A2 | MME 1459/4885ECE1 3732/4885CTSK 960/4885 |
| US-12150775-B2 | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | TPMT, FABP2, SLC10A2 | MME 1459/4885ECE1 3732/4885CTSK 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.